PERSHING SQ HLD LTD REG S by Pershing Square Holdings Ltd. Azioni (OTC: PSHZF)

Ultime notizie per PERSHING SQ HLD LTD REG S by Pershing Square Holdings Ltd. (OTC:PSHZF) Azioni

PERSHING SQ HLD LTD REG S by Pershing Square Holdings Ltd.

Jefferies analyst Antonio Pedro Cardoso initiates coverage on Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) with a Hold rating and announces Price Target of $7.3.

News

Price Target

Initiation

Analyst Ratings

VTEX

Jefferies Initiates Coverage On Vtex with Hold Rating, Announces Price Target of $7.3

Keybanc analyst Ken Newman upgrades United Rentals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>) from Sector Weight to Overweight and announces $865 price target.

Upgrades

Keybanc Upgrades United Rentals to Overweight, Announces $865 Price Target

Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock, payable on June 18, 2025, to shareholders of record at the close of business on June 4, 2025. This dividend payment represents a 7.7% increase to the quarterly cash dividend paid in June 2024.

Dividends

ODFL

Old Dominion Freight Line Board Raises Quarterly Cash Dividend By 7.7% From $0.26 To $0.28 Per Share

Cato (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATO#NYSE">CATO</a>) reported quarterly earnings of $0.17 per share. This is a 68.52 percent decrease over earnings of $0.54 per share from the same period last year. The company reported $170.24 million in sales this quarter. This is a 3.87 percent decrease over sales of $177.10 million the same period last year.

Earnings

CATO

Cato Q1 EPS $0.17 Down From $0.54 YoY, Sales $170.24M Down From $177.10M YoY

Needham analyst Mike Cikos reiterates Cognyte Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) from Hold to Hold.

Reiteration

CGNT

Needham Reiterates Hold on Cognyte Softwareto Hold

Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) sees FY2026 sales of $1.185 billion-$1.206 billion vs $1.19 billion analyst estimate.

Guidance

LSPD

Lightspeed Commerce Sees FY2026 Sales $1.185B-$1.206B vs $1.19B Est

NeoGenomics Announced The Commercial Launch Of c-MET CDx For NSCLC, Its C-MET Companion Diagnostic Immunohistochemistry (IHC) Assay

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Management to host conference call today at 8 am Eastern Time to discuss data
REDWOOD CITY, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, presented data at the TIDES USA annual meeting in San Diego, California. Codexis' presentations showcased its proprietary ECO Synthesis platform's ability to support siRNA manufacturing by reducing purification costs, improving process performance, and demonstrating the potential to control stereochemistry. In addition, three presentations from contract development and manufacturing organizations (CDMOs) including Bachem, Nitto Avecia, and ST Pharm validated the transferability of Codexis' ligation processes to their in-house facilities.

CDXS

Codexis Presents Data At TIDES USA Showcasing Proprietary ECO Synthesis Platform's Ability To Support siRNA Manufacturing By Reducing Purification Costs, Improving Process Performance, And Demonstrating Potential To Control Stereochemistry

Lightspeed Commerce Sees FY26 Revenue Growth Of Approximately 10%-12%; Projects Gross Profit Growth Of Approximately 14%

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) with a Buy and raises the price target from $25 to $31.

MDWD

HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $31

AAP: 26% &#x7C; <a href="https://www.benzinga.com//node/45561098">Advance Auto Parts shares are trading higher following better-than-expected Q1 financial results.</a>
&nbsp;
URBN: 18% &#x7C; <a href="https://www.benzinga.com//node/45560639">Urban Outfitters shares are trading higher following better-than-expected Q1 financial results.</a>
&nbsp;
NVTS: 238% &#x7C; <a href="https://www.benzinga.com//node/45552685">Navitas Semiconductor Collaborates With NVIDIA On Next-Gen 800V HVDC Architecture Using GaNFast And GeneSiC Technologies To Power AI Systems Like Rubin Ultra</a>

Movers

Trading Ideas

NVTS

URBN

Market-Moving News for May 22nd

<ul>
<li>2025 Full Year Total Revenue Guidance of $94 to $98 million</li>
<li>Delcath Announces Plan to Enter into National Medicaid Drug Rebate Agreement</li>
</ul>

DCTH

Delcath Systems Sees 2025 CHEMOSAT And HEPZATO KIT Revenue Climbing To $94M–$98M In 2025, Up Over 150% YoY, Sees 83%–85% Gross Margins

DA Davidson analyst Peter Heckmann downgrades Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) from Buy to Neutral and announces $226 price target.

Downgrades

GWRE

DA Davidson Downgrades Guidewire Software to Neutral, Announces $226 Price Target

Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) sees Q1 sales of $285.000 million-$290.000 million vs $288.45 million analyst estimate.

Lightspeed Commerce Sees Q1 Sales $285.000M-$290.000M vs $288.45M Est

Sionna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna's nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.

SION

Sionna Therapeutics To Present Preclinical Data Assessing Combinations Of NBD1 Stabilizers, SION-451 And SION-719, With Complementary Sionna CFTR Modulators, Galicaftor And SION-109, At ECFS 48th European Cystic Fibrosis Conference

HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgrades UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) from Buy to Neutral.

URGN

HC Wainwright & Co. Downgrades UroGen Pharma to Neutral

Sharps Technology, Inc. (Nasdaq: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces that it has received a notice from Nasdaq confirming that the Company has regained compliance with The Nasdaq's Capital Market's minimum bid price requirement of $1.00 per share and the minimum stockholders' equity requirement of $2.5 million.
The notice from Nasdaq indicates that the Company is in compliance with the Nasdaq Capital Market's listing requirements and the Company's common stock will continue to be listed and traded on Nasdaq.

STSS

Sharps Technology Regains Compliance With Nasdaq's Capital Market's Minimum Bid Price Requirement Of $1.00/Shr And Minimum Stockholders' Equity Requirement Of $2.5M

Analog Devices Sees Q3 Adj EPS $1.82-$2.02 vs $1.83 Est; Sees Sales $2.650B-$2.850B vs $2.62B Est

Needham analyst Ryan Koontz maintains Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) with a Buy and lowers the price target from $19 to $16.

Comments

PERSHING SQ HLD LTD REG S by Pershing Square Holdings Ltd.

Notizie

Ultime notizie per PERSHING SQ HLD LTD REG S by Pershing Square Holdings Ltd. (OTC:PSHZF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO